Effect of Captopril on GLS in Duchenne Myodystrophy
- Registration Number
- NCT06485661
- Lead Sponsor
- Ain Shams University
- Brief Summary
To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)
- Detailed Description
ACEI slowing down the onset and the progression of dystrophinopathic cardiomyopathy.
To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.
Exclusion Criteria
- Any patient who refuses to sign an informed consent.
- Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
- Reduced ejection fraction below 50%.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Duchenne patients subjected to captopril Captopril Tablets -
- Primary Outcome Measures
Name Time Method The impaired global longitudinal strain will change in echo in the number of participants with duchenne myodystrophy 6 months Impaired Global longitudinal strain will be changed in echo after 6 months of treatment with Captopril in patients with duchenne myodystrophy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ain Shams university
🇪🇬Cairo, Egypt